IP Library › Patent Application 17441403

Patent Application

App. No. 17/441,403

INHIBITORS OF RAF KINASES

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US None
App. No.: 17/441,403

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Claims (194)

1 . A compound, or pharmaceutically acceptable salt or solvate thereof, having the structure of Formula (I):

wherein,

G is C═O or SO 2 ;

R is C 1 -C 8 optionally substituted alkyl, —(C1-C8 optionally substituted alkylene)-OPO(OH) 2 , —(C1-C8 optionally substituted alkylene)-S(O)NHMe, C3-C6 optionally substituted cycloalkyl, —(C3-C6 optionally substituted cycloalkylene)-OPO(OH) 2 , C4-C6 optionally substituted cycloalkylalkyl, —(C3-C6 optionally substituted cycloalkylalkylene)-OPO(OH) 2 , C3-C6 optionally substituted heterocyclyl, —(C3-C6 optionally substituted heterocyclyl)-OPO(OH) 2 , C3-C6 optionally substituted heterocyclylalkyl, —(C3-C6 optionally substituted heterocyclylalkyl)-OPO(OH) 2 ;

X is N, C—H, C-D, C—F, or C—CH 3 ;

R 1 is C1-C3 optionally substituted alkyl, and q is 0, 1, or 2; or optionally, if q is 2, then two R 1 groups join to form a fused ring;

R 2 is H, D or F;

R 4 is halogen, optionally substituted C1-C3 alkyl, —CD 3 , or optionally substituted C1-C3 alkoxy;

R 6 is H, D, Cl or F;

R c is H or D;

Z is selected from:

(a) —NR a R b , wherein R a is selected from H, optionally substituted alkyl, optionally substituted C3-C6 alkenyl, optionally substituted C3-C6 alkynyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl; and

R b is selected from optionally substituted alkyl, optionally substituted C3-C6 alkenyl, optionally substituted C3-C6 alkynyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted C4-C6 heterocyclyl, or optionally substituted heterocyclylalkyl;

(b)

wherein m is 0, 1, 2, or 3; p is 0, 1, 2, 3, or 4; and

each R 11 is independently selected from amino, alkylamino, dialkylamino, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —S-alkyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl or two R 11 groups together form an oxo;

(c)

wherein m is 0, 1, 2, or 3; p is 0, 1, 2, 3, or 4;

W is O, S, S(O), SO 2 , NH or N(optionally substituted C1-C6 alkyl); and

each R 11 is independently selected from amino, alkylamino, dialkylamino, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl, or two R 11 groups together form an oxo;

(d)

wherein m is 0, 1, or 2; n is 0, 1, or 2; m1 is 0, 1, or 2; n1 is 0, 1, or 2 provided both m1 and n1 are not both 0; p is 0, 1, or 2; and q is 0, 1 or 2;

W is O, S, S(O), SO 2 , NH or N(optionally substituted C1-C6 alkyl), CH 2 , CHR 11 , or C(R 11 ) 2 ; and

each R 11 is independently selected from amino, alkylamino, dialkylamino, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl, or two R 11 groups together form an oxo;

(e)

wherein m is 0, 1, or 2; n is 0, 1, or 2; m1 is 1, or 2; p is 0, 1, 2, or 3; W is O, S, S(O), SO 2 , NH or N(optionally substituted C1-C6 alkyl), CH 2 , CHR 11 , —CH 2 —CH 2 —, —CH 2 —CHR 11 —, —CH 2 —C(R 11 ) 2 —, —CHR 11 —CH 2 —, —C(R 11 ) 2 —CH 2 —, —NH—CH 2 —, —NH—CHR 11 —, —NH—C(R 11 ) 2 —, —CH 2 —NH—, —CHR 11 —NH—, —C(R 11 ) 2 —NH—, —N(R 11 )—CH 2 —, —N(R 11 )—CHR 11 —, —N(R 11 )—C(R 11 ) 2 —, —CH 2 —N(R 11 )—, —CHR 11 —N(R 11 )—, —C(R 11 ) 2 —N(R 11 )—, —O—CH 2 —, or —CH 2 —O—; each R 11 is independently selected from amino, alkylamino, dialkylamino, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl, or two R 11 groups together form an oxo; and R 12 and R 13 are each independently selected from H, or optionally substituted C1-C6 alkyl;

(f)

wherein m is 0, 1, or 2; n is 0, 1, or 2; m1 is 0, 1, or 2; p is 0, 1, or 2;

W is O, S, S(O), S02, NH or N(optionally substituted C1-C6 alkyl), CH 2 , CHR 11 , or C(R 11 ) 2 each R 11 is independently selected from amino, alkylamino, dialkylamino, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl, or two R 11 groups together form an oxo;

and R 12 and R 13 are each independently selected from H, or optionally substituted C1-C6 alkyl;

(g)

wherein m is 0, 1, 2, or 3; n is 0, 1, 2, or 3 provided both m and n are not both 0; p is 0, 1, 2, 3, or 4; and

each R 11 is independently selected from —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl, or two R 11 groups together form an oxo;

(h)

wherein m is 1, 2, or 3; n is 1, 2, or 3; p is 0, 1, or 2; and

each R 13 or R 14 is independently selected from hydrogen, halogen, —CN, optionally substituted C1-C6 alkyl, or optionally substituted C3-C6 cycloalkyl; each R 11 is independently selected from —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl;

(i)

wherein m is 0, 1, or 2; n is 0, 1, or 2; m1 is 0, 1, or 2; p is 0, 1, or 2; and q is 0, 1 or 2; W is O, S, S(O), SO 2 , NH or N(optionally substituted C1-C6 alkyl), CH 2 , CHR 11 , or C(R 11 ) 2 ; and each R 11 is independently selected from amino, alkylamino, dialkylamino, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl, or two geminal R 11 groups together form an oxo.

2 . A compound, or pharmaceutically acceptable salt or solvate thereof, having the structure of Formula (II):

wherein

G is C═O or SO 2 ;

R is C1-C8 optionally substituted alkyl, —(C1-C8 optionally substituted alkylene)-OPO(OH) 2 , —(C1-C8 optionally substituted alkylene)-S(O)NHMe, C3-C6 optionally substituted cycloalkyl, —(C3-C6 optionally substituted cycloalkylene)-OPO(OH) 2 , C4-C6 optionally substituted cycloalkylalkyl, —(C3-C6 optionally substituted cycloalkylalkylene)-OPO(OH) 2 , C3-C6 optionally substituted heterocyclyl, —(C3-C6 optionally substituted heterocyclyl)-OPO(OH) 2 , C3-C6 optionally substituted heterocyclylalkyl, —(C3-C6 optionally substituted heterocyclylalkyl)-OPO(OH) 2 ;

X is N, C—H, C-D, C—F, or C—CH 3 ;

R 1 is C1-C3 optionally substituted alkyl, and q is 0, 1, or 2; or optionally, if q is 2, then two R 1 groups join to form a fused ring;

R 2 is H, D or F;

R 4 is halogen, optionally substituted C1-C3 alkyl, —CD3, or optionally substituted C1-C3 alkoxy;

R 6 is H, D, Cl or F;

R c is H or D;

Z is selected from:

(b)

wherein m is 0, 1, 2, or 3; p is 0, 1, 2, 3, or 4; and

(c)

wherein m is 0, 1, 2, or 3; p is 0, 1, 2, 3, or 4;

W is O, S, S(O), SO 2 , NH or N(optionally substituted C1-C6 alkyl); and

each R 11 is independently selected from amino, alkylamino, dialkylamino, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl, or two R 11 groups together form an oxo;

(d)

wherein m is 0, 1, or 2; n is 0, 1, or 2; m1 is 0, 1, or 2; n1 is 0, 1, or 2 provided both m1 and n1 are not both 0; p is 0, 1, or 2; and q is 0, 1 or 2;

W is O, S, S(O), SO 2 , NH or N(optionally substituted C1-C6 alkyl), CH 2 , CHR 11 , or C(R 11 ) 2 ; and

each R 11 is independently selected from amino, alkylamino, dialkylamino, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl, or two R 11 groups together form an oxo;

(e)

(f)

wherein m is 0, 1, or 2; n is 0, 1, or 2; m1 is 0, 1, or 2; p is 0, 1, or 2;

W is O, S, S(O), SO 2 , NH or N(optionally substituted C1-C6 alkyl), CH 2 , CHR 11 , or C(R 11 ) 2 each R 11 is independently selected from amino, alkylamino, dialkylamino, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl, or two R 11 groups together form an oxo;

and R 12 and R 13 are each independently selected from H, or optionally substituted C1-C6 alkyl;

(g)

wherein m is 0, 1, 2, or 3; n is 0, 1, 2, or 3 provided both m and n are not both 0; p is 0, 1, 2, 3, or 4; and

(h)

wherein m is 1, 2, or 3; n is 1, 2, or 3; p is 0, 1, or 2; and

(i)

3 . The compound of claim 1 or 2 , or pharmaceutically acceptable salt or solvate thereof, wherein G is C═O.

4 . The compound of any one of the preceding claims, or pharmaceutically acceptable salt or solvate thereof, wherein R c is hydrogen.

5 . The compound of any one of claims 1 - 4 , or pharmaceutically acceptable salt or solvate thereof, wherein R c is deuterium.

6 . The compound of any one of the preceding claims, or pharmaceutically acceptable salt or solvate thereof, wherein R 2 is hydrogen or deuterium.

7 . The compound of any one of the preceding claims, or pharmaceutically acceptable salt or solvate thereof, wherein R 6 is hydrogen or deuterium.

8 . The compound of any one of the preceding claims, or pharmaceutically acceptable salt or solvate thereof, wherein R 2 is F.

9 . The compound of any one of the preceding claims, or pharmaceutically acceptable salt or solvate thereof, wherein R 6 is F.

10 . The compound of any one of the preceding claims, or pharmaceutically acceptable salt or solvate thereof, wherein X is N.

11 . The compound of any one of claims 1 - 9 , or pharmaceutically acceptable salt or solvate thereof, wherein X is C—H or C-D.

12 . The compound of any one of claims 1 - 9 , or pharmaceutically acceptable salt or solvate thereof, wherein X is C—F.

13 . The compound of any one of the preceding claims, or pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally substituted C1 alkyl.

14 . The compound of any one of the preceding claims, or pharmaceutically acceptable salt or solvate thereof, wherein q is 0.

15 . The compound of any one of claims 1 - 13 , or pharmaceutically acceptable salt or solvate thereof, wherein q is 1.

16 . The compound of any one of claims 1 - 13 or 15 , or pharmaceutically acceptable salt or solvate thereof, wherein R 1 is CH 3 , q is 1, and R 1 is positioned to provide a 3-methylmorpholino.

17 . The compound of any one of the preceding claims, or pharmaceutically acceptable salt or solvate thereof, wherein R is C1-C8 optionally substituted alkyl.

18 . The compound of any one of claims 1 - 16 , or pharmaceutically acceptable salt or solvate thereof, wherein R is —(C1-C8 optionally substituted alkylene)-OPO(OH) 2 .

19 . The compound of any one of claims 1 - 16 , or pharmaceutically acceptable salt or solvate thereof, wherein R is C3-C6 optionally substituted cycloalkyl.

20 . The compound of any one of claims 1 - 16 , or pharmaceutically acceptable salt or solvate thereof, wherein R is C4-C6 optionally substituted cycloalkylalkyl.

21 . The compound of any one of claims 1 - 16 , or pharmaceutically acceptable salt or solvate thereof, wherein R is C3-C6 optionally substituted heterocyclyl.

22 . The compound of any one of claims 1 - 16 , or pharmaceutically acceptable salt or solvate thereof, wherein R is C3-C6 optionally substituted heterocyclylalkyl.

23 . The compound of claim 17 , or pharmaceutically acceptable salt or solvate thereof, wherein the C1-C8 optionally substituted alkyl is a C2 optionally substituted alkyl.

24 . The compound of claim 18 , or pharmaceutically acceptable salt or solvate thereof, wherein the —(C1-C8 optionally substituted alkylene)-OPO(OH) 2 is a C2 optionally substituted alkylene.

25 . The compound of any one of the preceding claims, or pharmaceutically acceptable salt or solvate thereof, wherein R 4 is halogen.

26 . The compound of any one of the preceding claims, or pharmaceutically acceptable salt or solvate thereof, wherein R 4 is optionally substituted C1-C3 alkyl.

27 . The compound of any one of the preceding claims, or pharmaceutically acceptable salt or solvate thereof, wherein R 4 is methyl.

28 . The compound of any one of the preceding claims, or pharmaceutically acceptable salt or solvate thereof, wherein Z is —NR a R b , wherein R a is selected from H, optionally substituted alkyl, optionally substituted C3-C6 alkenyl, optionally substituted C3-C6 alkynyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl; and

29 . The compound of claim 28 , or pharmaceutically acceptable salt or solvate thereof, wherein R a is H.

30 . The compound of claim 28 , or pharmaceutically acceptable salt or solvate thereof, wherein R a is optionally substituted alkyl.

31 . The compound of any one of claims 28 - 30 , or pharmaceutically acceptable salt or solvate thereof, wherein R b is optionally substituted alkyl.

32 . The compound of any one of claims 1 - 27 , or pharmaceutically acceptable salt or solvate thereof, wherein Z is

wherein m is 0, 1, 2, or 3; p is 0, 1, 2, 3, or 4; and each R 11 is independently selected from amino, alkylamino, dialkylamino, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl; or two R 11 groups together form an oxo.

33 . The compound of claim 32 , or pharmaceutically acceptable salt or solvate thereof, wherein m is 0.

34 . The compound of claim 32 , or pharmaceutically acceptable salt or solvate thereof, wherein m is 1.

35 . The compound of claim 32 , or pharmaceutically acceptable salt or solvate thereof, wherein m is 2.

36 . The compound of claim 32 , or pharmaceutically acceptable salt or solvate thereof, wherein m is 3.

37 . The compound of any one of claims 32 - 36 , or pharmaceutically acceptable salt or solvate thereof, wherein p is 0.

38 . The compound of any one of claims 32 - 36 , or pharmaceutically acceptable salt or solvate thereof, wherein p is 1.

39 . The compound of any one of claims 32 - 36 , or pharmaceutically acceptable salt or solvate thereof, wherein p is 2.

40 . The compound of any one of claims 32 - 36 , or pharmaceutically acceptable salt or solvate thereof, wherein p is 1.

41 . The compound of any one of claims 32 - 40 , or pharmaceutically acceptable salt or solvate thereof, wherein R 11 is optionally substituted C1-C6 alkyl, or optionally substituted C3-C6 cycloalkyl.

42 . The compound of claim 41 , or pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted C1-C6 alkyl, or optionally substituted C3-C6 cycloalkyl is substituted with at least a halogen.

43 . The compound of any one of claims 1 - 27 , or pharmaceutically acceptable salt or solvate thereof, wherein Z is

wherein m is 0, 1, 2, or 3; p is 0, 1, 2, 3, or 4; W is O, S, S(O), SO 2 , NH or N(optionally substituted C1-C6 alkyl); and

each R 11 is independently selected from amino, alkylamino, dialkylamino, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl, or two R 11 groups together form an oxo.

44 . The compound of claim 43 , or pharmaceutically acceptable salt or solvate thereof, wherein W is O.

45 . The compound of claim 43 , or pharmaceutically acceptable salt or solvate thereof, wherein W is S.

46 . The compound of any one of claims 43 - 45 , or pharmaceutically acceptable salt or solvate thereof, wherein m is 1, and n is 1.

47 . The compound of any one of claims 43 - 45 , or pharmaceutically acceptable salt or solvate thereof, wherein m is 1, and n is 2.

48 . The compound of any one of claims 43 - 47 , or pharmaceutically acceptable salt or solvate thereof, wherein R 11 is optionally substituted C1-C6 alkyl, or optionally substituted C3-C6 cycloalkyl.

49 . The compound of claim 48 , or pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted C1-C6 alkyl, or optionally substituted C3-C6 cycloalkyl is substituted with at least a halogen.

50 . The compound of any one of claims 1 - 27 , or pharmaceutically acceptable salt or solvate thereof, wherein Z is

wherein m is 0, 1, or 2; n is 0, 1, or 2; m1 is 0, 1, or 2; n1 is 0, 1, or 2 provided both m1 and n1 are not both 0; p is 0, 1, or 2; and q is 0, 1 or 2; W is O, S, S(O), SO 2 , NH or N(optionally substituted C1-C6 alkyl), CH 2 , CHR 11 , or C(R 11 ) 2 ; and each R 11 is independently selected from amino, alkylamino, dialkylamino, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl, or two R 11 groups together form an oxo.

51 . The compound of claim 50 , or pharmaceutically acceptable salt or solvate thereof, wherein m is 1, and n is 1.

52 . The compound of any one of claims 50 - 51 , or pharmaceutically acceptable salt or solvate thereof, wherein m is 0, and n is 2.

53 . The compound of any one of claims 50 - 52 , or pharmaceutically acceptable salt or solvate thereof, wherein m1 is 0, and n1 is 2.

54 . The compound of any one of claims 50 - 53 , or pharmaceutically acceptable salt or solvate thereof, wherein m1 is 1, and n1 is 1.

55 . The compound of any one of claims 50 - 54 , or pharmaceutically acceptable salt or solvate thereof, wherein W is O.

56 . The compound of any one of claims 50 - 54 , or pharmaceutically acceptable salt or solvate thereof, wherein W is CH 2 .

57 . The compound of any one of claims 50 - 54 , or pharmaceutically acceptable salt or solvate thereof, wherein W is CHR 11 .

58 . The compound of any one of claims 50 - 54 , or pharmaceutically acceptable salt or solvate thereof, wherein W is C(R 11 ) 2 .

59 . The compound of any one of claims 57 - 58 , or pharmaceutically acceptable salt or solvate thereof, wherein R 11 is halogen and q is 1.

60 . The compound of any one of claims 1 - 27 , or pharmaceutically acceptable salt or solvate thereof, wherein Z is

wherein m is 0, 1, or 2; n is 0, 1, or 2; m1 is 1, or 2; p is 0, 1, 2, or 3; W is O, S, S(O), SO 2 , NH or N(optionally substituted C1-C6 alkyl), CH 2 , CHR 11 , —CH 2 —CH 2 —, —CH 2 —CHR 11 —, —CH 2 —C(R 11 ) 2 —, —CHR 11 —CH 2 —, —C(R 11 ) 2 —CH 2 —, —NH—CH 2 —, —NH—CHR 11 —, —NH—C(R 11 ) 2 —, —CH 2 —NH—, —CHR 11 —NH—, —C(R 11 ) 2 —NH—, —N(R 11 )—CH 2 —, —N(R 11 )—CHR 11 —, —N(R 11 )—C(R 11 ) 2 —, —CH 2 —N(R 11 )—, —CHR 11 —N(R 11 )—, —C(R 11 ) 2 —N(R 11 )—; each R 11 is independently selected from amino, alkylamino, dialkylamino, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl, or two R 11 groups together form an oxo; and R 12 and R 13 are each independently selected from H, or optionally substituted C1-C6 alkyl.

61 . The compound of claim 60 , or pharmaceutically acceptable salt or solvate thereof, wherein m is 0, n is 1, and m1 is 1; and W is —O—CH 2 —, or —CH 2 —O—.

62 . The compound of any one of claims 1 - 27 , or pharmaceutically acceptable salt or solvate thereof, wherein Z is

wherein m is 0, 1, or 2; n is 0, 1, or 2; m1 is 0, 1, or 2; p is 0, 1, or 2; W is O, S, S(O), SO 2 , NH or N(optionally substituted C1-C6 alkyl), CH 2 , CHR 11 , or C(R 11 ) 2 ; each R 11 is independently selected from amino, alkylamino, dialkylamino, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl, or two R 11 groups together form an oxo; and R 12 and R 13 are each independently selected from H, or optionally substituted C1-C6 alkyl.

63 . The compound of claim 62 , or pharmaceutically acceptable salt or solvate thereof, wherein W is O.

64 . The compound of any one of claims 62 - 63 , or pharmaceutically acceptable salt or solvate thereof, wherein W is CH 2 , or CHR 11 .

65 . The compound of any one of claims 62 - 64 , or pharmaceutically acceptable salt or solvate thereof, wherein m1 is 0.

66 . The compound of any one of claims 62 - 64 , or pharmaceutically acceptable salt or solvate thereof, wherein m1 is 1.

67 . The compound of any one of claims 62 - 66 , or pharmaceutically acceptable salt or solvate thereof, wherein m is 1 and n is 1.

68 . The compound of any one of claims 62 - 66 , or pharmaceutically acceptable salt or solvate thereof, wherein m is 1 and n is 0.

69 . The compound of any one of claims 62 - 66 , or pharmaceutically acceptable salt or solvate thereof, wherein m is 0 and n is 1.

70 . The compound of any one of claims 1 - 27 , or pharmaceutically acceptable salt or solvate thereof, wherein Z is

wherein m is 0, 1, 2, or 3; n is 0, 1, 2, or 3 provided both m and n are not both 0; p is 0, 1, 2, 3, or 4; and

each R 11 is independently selected from amino, alkylamino, dialkylamino, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl.

71 . The compound of claim 70 , or pharmaceutically acceptable salt or solvate thereof, wherein m is 1, and n is 1.

72 . The compound of claim 70 , or pharmaceutically acceptable salt or solvate thereof, wherein m is 1, and n is 2.

73 . The compound of any one of claims 70 - 72 , or pharmaceutically acceptable salt or solvate thereof, wherein p is 1.

74 . The compound of any one of claims 70 - 72 , or pharmaceutically acceptable salt or solvate thereof, wherein p is 2.

75 . The compound of any one of claims 70 - 74 , or pharmaceutically acceptable salt or solvate thereof, wherein at least one R 11 is attached to an alkene carbon.

76 . The compound of any one of claims 70 - 74 , or pharmaceutically acceptable salt or solvate thereof, wherein at least one R 11 is not attached to an alkene carbon.

77 . The compound of any one of claims 70 - 76 , or pharmaceutically acceptable salt or solvate thereof, wherein R 11 is optionally substituted C1-C6 alkyl, or optionally substituted C3-C6 cycloalkyl.

78 . The compound of any one of claims 70 - 72 , or pharmaceutically acceptable salt or solvate thereof, wherein p is 0.

79 . The compound of any one of claims 1 - 27 , or pharmaceutically acceptable salt or solvate thereof, wherein Z is

wherein m is 1, 2, or 3; n is 1, 2, or 3; p is 0, 1, or 2; and each R 13 or R 14 is independently selected from hydrogen, halogen, —CN, optionally substituted C1-C6 alkyl, or optionally substituted C3-C6 cycloalkyl; each R 11 is independently selected from amino, alkylamino, dialkylamino, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C1-C6 alkoxy, optionally substituted C2-C6 alkynyl, optionally substituted —SO 2 alkyl, optionally substituted C3-C6 cycloalkylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl.

80 . The compound of claim 79 , or pharmaceutically acceptable salt or solvate thereof, wherein m is 2, and n is 1.

81 . The compound of claim 79 or 80 , or pharmaceutically acceptable salt or solvate thereof, wherein p is 0.

82 . The compound of claim 79 or 80 , or pharmaceutically acceptable salt or solvate thereof, wherein p is 1.

83 . The compound of any one of claims 79 - 82 , or pharmaceutically acceptable salt or solvate thereof, wherein one of R 13 or R 14 is not hydrogen.

84 . The compound of any one of claims 79 - 83 , or pharmaceutically acceptable salt or solvate thereof, wherein one of R 13 or R 14 is optionally substituted C1-C6 alkyl.

85 . The compound of claim 84 , or pharmaceutically acceptable salt or solvate thereof, wherein R 13 is optionally substituted C1-C6 alkyl.

86 . The compound of claim 84 , or pharmaceutically acceptable salt or solvate thereof, wherein R 14 is optionally substituted C1-C6 alkyl.

87 . The compound of any one of claims 1 - 27 , or pharmaceutically acceptable salt or solvate thereof, wherein Z is

88 . The compound of claim 87 , or pharmaceutically acceptable salt or solvate thereof, wherein W is O.

89 . The compound of claim 87 or 88 , or pharmaceutically acceptable salt or solvate thereof, wherein m is 2, and n is 1.

90 . The compound of any one of claims 87 - 89 , or pharmaceutically acceptable salt or solvate thereof, wherein m1 is 1 or 2.

91 . The compound of any one of claims 87 - 90 , or pharmaceutically acceptable salt or solvate thereof, wherein p is 0 or 1, and q is 0 or 1.

92 . A compound, or pharmaceutically acceptable salt or solvate thereof, selected from a compound described in Table 1.

93 . A pharmaceutical composition comprising a compound of Formula (I), or pharmaceutically acceptable salt or solvate thereof, as described in any one of claim 1 or 3 - 91 .

94 . A pharmaceutical composition comprising a compound of Formula (II), or pharmaceutically acceptable salt or solvate thereof, as described in any one of claims 2 - 91 .

95 . A pharmaceutical composition comprising a compound as described in claim 92 , or pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

96 . A pharmaceutical composition comprising a compound of Formula (III)-(VI), or pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

97 . A method of preparing a pharmaceutical composition comprising mixing a compound, or pharmaceutically acceptable salt or solvate thereof, of any one of claims 1 - 92 , and a pharmaceutically acceptable carrier.

98 . A compound of any one of claims 1 - 92 or pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of the human or animal body.

99 . A compound of any one of claims 1 - 92 , or pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of cancer or neoplastic disease.

100 . Use of a compound of any one of claims 1 - 92 , or pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of cancer or neoplastic disease.

101 . A method of treating cancer in a patient in need thereof comprising administering to the patient a compound of Formula (I) as described in any one of claim 1 or 3 - 91 , or pharmaceutically acceptable salt or solvate thereof.

102 . A method of treating cancer in a patient in need thereof comprising administering to the patient a pharmaceutical composition comprising a compound of Formula (I) as described in any one of claim 1 or 3 - 91 , or pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

103 . A method of treating cancer in a patient in need thereof comprising administering to the patient a compound of Formula (II) as described in any one of claims 2 - 91 , or pharmaceutically acceptable salt or solvate thereof.

104 . A method of treating cancer in a patient in need thereof comprising administering to the patient a pharmaceutical composition comprising a compound of Formula (II) as described in any one of claims 2 - 91 , or pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

105 . A method of treating cancer in a patient in need thereof comprising administering to the patient a compound as described in claim 92 , or pharmaceutically acceptable salt or solvate thereof.

106 . A method of treating cancer in a patient in need thereof comprising administering to the patient a pharmaceutical composition comprising a compound as described in claim 92 , or pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

107 . A method of treating cancer in a patient in need thereof comprising administering to the patient a compound of Formula (III)-(VI), or pharmaceutically acceptable salt or solvate thereof.

108 . A method of treating cancer in a patient in need thereof comprising administering to the patient a pharmaceutical composition comprising a compound of Formula (III)-(VI), or pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

109 . The method of any one of claims 101 - 108 wherein the cancer is breast cancer, colorectal cancer, ovarian cancer, pancreatic cancer, prostate cancer, or lung cancer.

Assignments (3)

CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE RECEIVING PARTY DATA COMPANY NAME IS: PIERRE FABRE MEDICAMENT PREVIOUSLY RECORDED AT REEL: 66638 FRAME: 147. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 11, 2024

From: KINNATE BIOPHARMA INC.

To: PIERRE FABRE MÉDICAMENT

Reel/Frame 068939/0656 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2024

From: KINNATE BIOPHARMA INC.

To: PIERRE FABRE MÉDICAMENT, SAS

Reel/Frame 066638/0147 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2022

From: KALDOR, STEPHEN W.; KANOUNI, TOUFIKE; MURPHY, ERIC A.; ARNOLD, LEE D.; TYHONAS, JOHN

To: KINNATE BIOPHARMA INC.

Reel/Frame 061717/0109 →